Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Neurofilament proteins (Nf) have been validated and established as a reliable body fluid
biomarker for neurodegenerative pathology. This review covers seven Nf isoforms, Nf light …

The identification of molecular biomarkers in CSF from individuals affected by Huntington
disease may help improve predictions of disease onset, better define disease progression …

Huntington's disease (HD) is characterized by clinical motor impairment (eg, involuntary
movements, poor coordination, parkinsonism), cognitive deficits, and psychiatric symptoms …

Recombinant adeno‐associated virus (AAV) is currently the most widely used platform for in
vivo gene therapy. Clinical pharmacology is a central field for AAV gene therapy …

Summary Background The recently proposed Huntington's Disease Integrated Staging
System (HD-ISS) categorises individuals with the Huntintin genetic mutation into disease …

Measuring Huntingtin (HTT) protein in peripheral cells represents an essential step in
biomarker discovery for Huntington's Disease (HD), however to date, investigations into the …

Huntington's disease is a progressive neurodegenerative disease caused by mutation of the
huntingtin (HTT) gene. The identification of mutation carriers before symptom onset provides …

Parkin et al. 1 propose the use of blood neurofilament light (NfL) levels as an enrichment
biomarker for individuals with Huntington's disease (HD) who may be classified as …

We have developed an inducible Huntington's disease (HD) mouse model that allows
temporal control of whole-body allele-specific mutant huntingtin (mHtt) expression. We …